The venture-backed medical device company, Metavention, was founded in 2012 and focuses on developing innovative glucose control therapy for patients with Type 2 diabetes. Their transcatheter devices utilize standard interventional vascular techniques to modulate sympathetic nervous system activity, providing physicians with a new tool for diagnosing and treating patients with Type 2 diabetes. Additionally, Metavention also develops medical devices to assist with interventional therapies for high blood pressure and other metabolic diseases.